-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A potential new treatment for Parkinson's disease developed by researchers at Rush University Medical Center has succeeded in slowing the progression of the disease in mice
In a study published in Nature Communications, Rush’s researchers found that two different peptides (amino acid chains) help slow the spread of synuclein
"Currently, there are no treatments to slow the progression of Parkinson's disease-they only treat symptoms," Rush University Medical Center Floyd A.
Lewy bodies are also associated with the development of Lewy body dementia and a rare neurological disease, multiple system atrophy (MSA)
In this study, the peptides developed in the laboratory are called the tlr2 interaction domain (TIDM) and nemo binding domain (NBD) of Myd88
Pahan said: "If these results can be replicated in patients, this will be a significant advancement in the treatment of destructive neurological disorders
This research was funded by the National Institutes of Health
DOI
10.
Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo
